Breast cancer risk management.

摘要: Abstract Breast cancer is a devastating illness that affects tens of thousands American women each year. Although no one can predict who will actually develop breast cancer, number risk factors have been found allow clinicians to identify the at highest risk. Recent research has focused on exploring options, such as chemoprevention, prevent high-risk from developing cancer. The selective estrogen receptor (ER) modulators (SERMs) were logical choice for chemoprevention because their well-known antagonist effects in breast. Tamoxifen best studied these agents and shown reduce incidence all cancers by 38% ER-positive tumors 48%. 1 However, despite this large potential reduction, management with chemopreventive still not routine. primary deterrents are believed be significant adverse events associated tamoxifen well perceived decline quality life (QOL). 2–4 These concerns led researchers consider other possible would effective but fewer or more acceptable side than tamoxifen. Raloxifene was proposed an alternative based its relative safety osteoporosis agent. In article, we review trials emergence both raloxifene then offer strategy prevention care setting.